Unhappy HGS investors vent in merger suit; New NuPathe chief scouts cash; Biocon plans psoriasis drug launch;

NEW! Conversations on Twitter :

• Buckle up – With influx of generics & another failure, insiders prepare for pharma earnings calls (AZ, Roche & Sanofi today).  See conversations here, here, and here.
  Input from @RyanMFierce, @kristen_hallam, @baruch_harris and @adamfeuerstein
• Should science writers shy away from jargon?
  Conversation related to article on @naturenews

 @FierceBiotech: GE, iBio unite on plant-based production of vaccines and biologics. Item | Follow @FierceBiotech

 @JohnCFierce: EIU on Astra: "So far the departure of boss David Brennan in June seems to have made little difference to the gloom surrounding the company."  | Follow @JohnCFierce

 @RyanMFierce: Science journos spend lots of time translating jargon into simple terms. Nature argues against some of this practice. Article | Follow @RyanMFierce

> Unhappy Human Genome Sciences ($HGSI) investors have filed suit against the biotech, saying they didn't do enough to win an acceptable price for the company. GSK ($GSK) has struck a deal to buy HGS for about $3 billion. Story

> The new CEO at NuPathe, Armando Anido, says his first take at the biotech will be to raise more money. The biotech recently resubmitted its NDA for the migraine treatment Zelrix. Story

> Biocon chief Kiran Mazumdar-Shaw says the company is planning on a near-term launch of a new psoriasis drug. Report

> Regeneron ($REGN) is planning about 85 new hires at its plant in East Greenbush. Story

Pharma News

 @FiercePharma: The common cry from Big Pharma this quarter: Europe's dreadful. And Parallel trade makes it worse--Reuters. More | Follow @FiercePharma

> Generic Seroquel drags AZ sales down by $900M. Article

> Sanofi cost-cutting plans overshadow sales strength. Story

> India's Lupin shops for U.S. brands to bolster margins. News

> Cancer drugs lift Roche sales as charges slash earnings. More

Medical Device News

@FierceMedDev: Hill-Rom has snatched up Aspen Surgical Products for $400 million. Release | Follow @FierceMedDev

 @MarkHFierce: The fight goes on. Advamed, via Abiomed's Michael Minogue, are pushing Congress to repeal the 2.3% device tax. More | Follow @MarkHFierce

 @DamianFierce: Boston Scientific posted a $3.4B second-quarter loss, citing sluggish markets abroad. News | Follow @DamianFierce

> Covidien tops expectations on strong device sales. Article

> Bard's sales rise slightly, nicked by foreign exchange rates. Report

> Device giant Terumo seeks merger with Olympus. More

Pharma Manufacturing News

> FDA ravages Sanofi vaccine sterility process in warning letter. Article

> Sun Pharma standardizing manufacturing globally. Story

> California county orders drugmakers to pay for drug disposal. News

> FDA to Congress: Agency can't dodge plant problems to avoid shortages. More

Vaccines News

> FDA wags finger at Sanofi for no-nos at vaccine plants. News

> GE, iBio unite on plant-based production of vaccines and biologics. Item

> Sanofi vaccine combats most viral causes of dengue. Story

> Researchers hope to turn white blood cells into a vaccine. More

> Medicago completes rapid-fire flu vaccine production. Article

> Vaxil BioTherapeutics debuts on Tel Aviv Stock Exchange. Item